On February 10, 2026, President Trump acquired between $1 million and $5 million in Axon Enterprise stock, a company that produces Tasers and other policing technology. This purchase occurred shortly before ICE announced a request for information regarding a $220 million contract for approximately 17,800 Tasers, which experts suggest is tailored to Axon's products.
Although the White House claims there are no conflicts of interest, the timing of Trump's investment and the ICE notice has drawn scrutiny from ethics experts and civil rights advocates. They express concern that Trump's financial interests could influence federal procurement decisions, particularly as Axon already supplies the federal government with Tasers.
The potential contract, if awarded, would significantly expand ICE's Taser inventory and could lead to further business for Axon in the policing sector, which is already experiencing record demand. Following Trump's stock purchase, Axon's shares rose over 22% in the subsequent month, indicating a possible financial benefit from the timing of the investment.
However, there is no evidence that Trump was involved in the procurement process or that Axon had prior knowledge of his stock purchase. The situation highlights the complexities of ethics in government and business, especially regarding the intersection of personal investments and public policy